The WHO Model List of Essential Medicines for Children is a list, proposed by the World Health Organization (WHO), of the most effective and safe medicines for use in children up to 12 years of age needed to meet the most important needs in a basic health-care system. The list is divided into core items and complementary items. The core items are deemed to be the most cost effective options for key health problems and are usable with little additional health care resources. The complementary items frequently require additional infrastructure such as specially trained health care providers or diagnostic equipment. The first list for children was created in 2007, and the list is in its 7th edition as of 2019[update].
Note: In the following article, an α indicates the medicine is a complementary item, for which specialized diagnostic or monitoring and/or specialist training are needed. An item may also be listed as complementary on the basis of higher costs and/or a less attractive cost/benefit ratio.
^There may be a role for sedating antihistamines for limited indications.
^as adjunctive therapy for treatment-resistant partial or generalized seizures.
^for buccal administration when solution for oromucosal administration is not available
^cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability.
^Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable.
^single agent trimethoprim may be an alternative for lower urinary tract infection.
^also listed for single-dose treatment of trachoma and yaws.
^3rd generation cephalosporin of choice for use in hospitalised neonates.
^Do not administer with calcium and avoid in infants with hyperbilirubinaemia.
^For treatment of chronic pulmonary aspergillosis, acute invasive aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients.
^For treatment of chronic pulmonary aspergillosis and acute invasive aspergillosis.
^for use in second-line regimens in accordance with WHO treatment guidelines
^For the treatment of viral haemorrhagic fevers only.
^Severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients
^For the treatment of cytomegalovirus retinitis (CMVr).
^World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN9789241210300. ISSN0512-3054. WHO technical report series;1021.